Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Dren Bio
National Institutes of Health Clinical Center (CC)
AVM Biotechnology Inc
Children's Hospital of Philadelphia
Ohio State University Comprehensive Cancer Center
Arovella Therapeutics Ltd
St. Justine's Hospital
Georgetown University
Eastern Cooperative Oncology Group
Medical College of Wisconsin
CRISPR Therapeutics
AstraZeneca
AvenCell Therapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute
University of Chicago
Vironexis Biotherapeutics Inc.
Memorial Sloan Kettering Cancer Center
Karolinska University Hospital
City of Hope Medical Center
University of Nebraska
Pfizer
Thomas Jefferson University
Fate Therapeutics
Syndax Pharmaceuticals
Center for International Blood and Marrow Transplant Research
Incyte Corporation
Massachusetts General Hospital
M.D. Anderson Cancer Center
Allogene Therapeutics
BeOne Medicines
University of Chicago
H. Lee Moffitt Cancer Center and Research Institute
Penn State University
Columbia University
Ossium Health, Inc.
Ossium Health, Inc.
Zhejiang University
University of Miami
City of Hope Medical Center
Seattle Children's Hospital
Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud - IDCBIS
Dana-Farber Cancer Institute
Washington University School of Medicine
Institute of Hematology & Blood Diseases Hospital, China
GeoVax, Inc.
Dana-Farber Cancer Institute
Stanford University
Center for International Blood and Marrow Transplant Research